FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2960652128> ?p ?o ?g. }

• W2960652128 abstract "Basic blue 3 is a promising anti-malarial lead compound based on the π-delocalized lipophilic cation hypothesis. Its derivatives with nitrogen atoms bonded to carbon atoms at the 3- and 7-positions on the phenoxazine ring were previously shown to exert potent antiprotozoal activity against Plasmodium falciparum, Trypanosoma cruzi, Trypanosoma brucei rhodesiense, and Leishmania donovani parasites in vitro. However, compounds with nitrogen modification at the 10-position on the phenoxazine ring were not evaluated. Six acylphenoxazine derivatives (ITT-001 to 006) with nitrogen modification at the 10-position on the phenoxazine ring, which were synthesized from basic blue 3, were characterized and evaluated for anti-malarial activity in vitro with an automated haematology analyzer (XN-30) and light microscopy. Intensity of self-fluorescence was measured using a fluorometer. Localization of basic blue 3 was observed by fluorescence microscopy. Cytotoxicity was evaluated using human cell lines, HEK293T and HepG2 cells. Finally, anti-malarial activity was evaluated in a rodent malaria model. All the six derivatives showed anti-malarial efficacy even against chloroquine-, pyrimethamine-, and artemisinin-resistant field isolates similar to the sensitive strains and isolates in vitro. The efficacy of basic blue 3 was the strongest, followed by that of ITT-001 to 004 and 006, while that of ITT-005 was the weakest. Basic blue 3 showed strong self-fluorescence, whereas ITT derivatives had five- to tenfold lower intensity than that of basic blue 3, which was shown by fluorescence microscopy to be selectively accumulated in the plasmodial cytoplasm. In contrast, ITT-003, 004, and 006 exhibited the lowest cytotoxicity in HEK293T and HepG2 cells in vitro and the highest selectivity between anti-malarial activity and cytotoxicity. The in vivo anti-malarial assay indicated that oral administration of ITT-004 was the most effective against the rodent malaria parasite, Plasmodium berghei NK65 strain. The six ITT derivatives were effective against chloroquine- and pyrimethamine-resistant strains and artemisinin-resistant field isolates as well as the sensitive ones. Among them, ITT-004, which had high anti-malarial activity and low cytotoxicity in vitro and in vivo, is a promising anti-malarial lead compound." @default.
• W2960652128 created "2019-07-23" @default.
• W2960652128 creator A5004244913 @default.
• W2960652128 creator A5016846269 @default.
• W2960652128 creator A5026879845 @default.
• W2960652128 creator A5036785289 @default.
• W2960652128 creator A5036911134 @default.
• W2960652128 creator A5047305720 @default.
• W2960652128 creator A5048185534 @default.
• W2960652128 creator A5083759507 @default.
• W2960652128 creator A5090656487 @default.
• W2960652128 date "2019-07-15" @default.
• W2960652128 modified "2023-10-15" @default.
• W2960652128 title "In vitro and in vivo characterization of anti-malarial acylphenoxazine derivatives prepared from basic blue 3" @default.
• W2960652128 cites W1969503178 @default.
• W2960652128 cites W1997704670 @default.
• W2960652128 cites W2005561713 @default.
• W2960652128 cites W2013100606 @default.
• W2960652128 cites W2017461858 @default.
• W2960652128 cites W2020251171 @default.
• W2960652128 cites W2020465799 @default.
• W2960652128 cites W2023224492 @default.
• W2960652128 cites W2033634323 @default.
• W2960652128 cites W2040713555 @default.
• W2960652128 cites W2057545963 @default.
• W2960652128 cites W2064880817 @default.
• W2960652128 cites W2076108308 @default.
• W2960652128 cites W2081796762 @default.
• W2960652128 cites W2088329399 @default.
• W2960652128 cites W2095745314 @default.
• W2960652128 cites W2101214661 @default.
• W2960652128 cites W2114296160 @default.
• W2960652128 cites W2114388515 @default.
• W2960652128 cites W2132093894 @default.
• W2960652128 cites W2135926190 @default.
• W2960652128 cites W2161311583 @default.
• W2960652128 cites W2171102256 @default.
• W2960652128 cites W2171526995 @default.
• W2960652128 cites W2313537425 @default.
• W2960652128 cites W2337606069 @default.
• W2960652128 cites W2347194041 @default.
• W2960652128 cites W2590767446 @default.
• W2960652128 cites W2795159665 @default.
• W2960652128 cites W2803145967 @default.
• W2960652128 cites W2916899099 @default.
• W2960652128 cites W2918099791 @default.
• W2960652128 cites W2950988468 @default.
• W2960652128 cites W2951217880 @default.
• W2960652128 doi "https://doi.org/10.1186/s12936-019-2873-0" @default.
• W2960652128 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6631887" @default.
• W2960652128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31307493" @default.
• W2960652128 hasPublicationYear "2019" @default.
• W2960652128 type Work @default.
• W2960652128 sameAs 2960652128 @default.
• W2960652128 citedByCount "3" @default.
• W2960652128 countsByYear W29606521282022 @default.
• W2960652128 countsByYear W29606521282023 @default.
• W2960652128 crossrefType "journal-article" @default.
• W2960652128 hasAuthorship W2960652128A5004244913 @default.
• W2960652128 hasAuthorship W2960652128A5016846269 @default.
• W2960652128 hasAuthorship W2960652128A5026879845 @default.
• W2960652128 hasAuthorship W2960652128A5036785289 @default.
• W2960652128 hasAuthorship W2960652128A5036911134 @default.
• W2960652128 hasAuthorship W2960652128A5047305720 @default.
• W2960652128 hasAuthorship W2960652128A5048185534 @default.
• W2960652128 hasAuthorship W2960652128A5083759507 @default.
• W2960652128 hasAuthorship W2960652128A5090656487 @default.
• W2960652128 hasBestOaLocation W29606521281 @default.
• W2960652128 hasConcept C185592680 @default.
• W2960652128 hasConcept C203014093 @default.
• W2960652128 hasConcept C2778048844 @default.
• W2960652128 hasConcept C2778371730 @default.
• W2960652128 hasConcept C2778716775 @default.
• W2960652128 hasConcept C2780374932 @default.
• W2960652128 hasConcept C55493867 @default.
• W2960652128 hasConcept C86803240 @default.
• W2960652128 hasConcept C98274493 @default.
• W2960652128 hasConceptScore W2960652128C185592680 @default.
• W2960652128 hasConceptScore W2960652128C203014093 @default.
• W2960652128 hasConceptScore W2960652128C2778048844 @default.
• W2960652128 hasConceptScore W2960652128C2778371730 @default.
• W2960652128 hasConceptScore W2960652128C2778716775 @default.
• W2960652128 hasConceptScore W2960652128C2780374932 @default.
• W2960652128 hasConceptScore W2960652128C55493867 @default.
• W2960652128 hasConceptScore W2960652128C86803240 @default.
• W2960652128 hasConceptScore W2960652128C98274493 @default.
• W2960652128 hasIssue "1" @default.
• W2960652128 hasLocation W29606521281 @default.
• W2960652128 hasLocation W29606521282 @default.
• W2960652128 hasLocation W29606521283 @default.
• W2960652128 hasLocation W29606521284 @default.
• W2960652128 hasOpenAccess W2960652128 @default.
• W2960652128 hasPrimaryLocation W29606521281 @default.
• W2960652128 hasRelatedWork W1980079347 @default.
• W2960652128 hasRelatedWork W1993866564 @default.
• W2960652128 hasRelatedWork W1998637266 @default.
• W2960652128 hasRelatedWork W2041559206 @default.
• W2960652128 hasRelatedWork W2065019097 @default.
• W2960652128 hasRelatedWork W2088063203 @default.
• W2960652128 hasRelatedWork W2113539543 @default.

• next